About Us

We are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates to address the world’s most life-threatening diseases and public health threats. Our History can be traced back to June 2007.


In June 2007,Sichuan Clover was established as a research laboratory.

In July 2016,Sichuan Clover entered into an agreement to establish and build 32,000 sqm commercial-scale cGMP biomanufacturing facility in Changxing, Zhejiang Province, China.

In December 2017,We completed the Series A Investment and raised approximately RMB62.8 million.

In June 2018,Our first patient was dosed with SCB-313 for treatment of cancer patients with malignant ascites in Phase 1 clinical trial.

In November 2019,We completed the Series B Investment and raised approximately RMB304.1 million.

In January 2020,we initiated development of SCB-2019, our COVID-19 vaccine candidate.

In April 2020,We established a collaboration and received funding from CEPI for SCB-2019.

In June 2020,We completed the Series B-2 Investment and raised approximately RMB171.8 million.

In June 2020,Our first participant was dosed with SCB-2019 (CpG 1018/Alum) in Phase I clinical trial.

In November 2020,CEPI expanded our partnership and increased funding up to $328 million for SCB-2019 development through licensure.

In December 2020,We announced positive Phase 1 data for SCB-2019 (CpG 1018/Alum), our COVID-19 vaccine candidates.

In February 2021,We completed the Series C financing raising approximately US$230 million.

In March 2021,We initiated SPECTRA, a pivotal global Phase 2/3 clinical trial evaluating SCB 2019 (CpG 1018/Alum) for vaccine efficacy and dosed the first participant at a clinical trial site located in the Philippines.